Advertisement

Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation

  • E. A. Aalbersberg
  • B. J. de Wit – van der Veen
  • M. W. J. Versleijen
  • L. J. Saveur
  • G. D. Valk
  • M. E. T. Tesselaar
  • M. P. M. Stokkel
Original Article
  • 10 Downloads

Abstract

Introduction

Somatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET). Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging. The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of 68Ga-DOTATATE intra-individually 1 day prior to and 1 day post injection of lanreotide.

Methods

Thirty-four patients with metastatic and/or unresectable NET and currently on lanreotide therapy for at least 4 months were included in the study. A 68Ga-DOTATATE PET/CT scan was performed on the day before and the day after lanreotide injection. In each patient 68Ga-DOTATATE uptake (SUVmax, mean, peak) was assessed in both tumour lesions and normal tissue. All scans were assessed by two blinded nuclear medicine physicians for visual analysis. Paired T-tests were performed to determine the differences between the scans.

Results

Of the 34 patients included, 31 were available for analyses in which 190 tumour lesions were measured. Uptake of 68Ga-DOTATATE in tumour lesions was increased significantly after lanreotide, but decreased significantly in the liver, spleen, and thyroid gland resulting in a higher tumour-to-liver ratio.

Conclusion

Lanreotide injection prior to 68Ga-DOTATATE PET/CT does not result in decreased tumour uptake. In contrast, tumour uptake was increased, whereas the uptake in normal organs is decreased, leading to an increased tumour-to-liver ratio. However, these differences were small and not deemed clinically relevant. These results strongly suggest that discontinuation of lanreotide injections in the weeks prior to 68Ga-DOTATATE PET examinations is unnecessary and does not compromise nuclear medicine imaging results.

Keywords

Neuroendocrine Tumours 68Ga-DOTATATE PET/CT Lanreotide 

Notes

Compliance with ethical standards

Disclosure statement

This research was supported by an unrestricted grant from Ipsen. Ipsen was not involved in the conduct of the study or the drafting of the manuscript, but did complete a courtesy review of the final version before submission.

Ethical statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991–1002.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;77030:1335–42.CrossRefGoogle Scholar
  3. 3.
    Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30(Suppl 1):3–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2–clinical implications. J Cell Mol Med. 2010;14:2585–91.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Caplin ME, Pavel M, Cwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259–77.CrossRefPubMedGoogle Scholar
  8. 8.
    Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester H-J, et al. Internalization of sst 2, sst 3, and sst 5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502–11.PubMedGoogle Scholar
  10. 10.
    de Jong M, Breeman WAP, Bernard BF, van Gameren A, Schaar M, Bakker WH, et al. Tumor uptake of the radiolabeled somatostatin analog [DOTA- 0,Tyr-3] octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.CrossRefPubMedGoogle Scholar
  12. 12.
    Haug AR, Rominger A, Mustafa M, Auernhammer C, Goke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of 68 Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52:1679–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Ayati N, Lee ST, Zakavi SR, Pathmaraj K, Qatawneh L, Poon A, et al. Long-acting somatostatin analog therapy differentially alters 68 Ga-DOTATATE uptake in normal tissues compared to primary tumors and metastatic lesions. J Nucl Med. 2017;59:223–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Janson E, Kalkner K, Eriksson B, Westlin J, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol. 1999;26:877–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Virgolini I, Ambrosini V, Bomanji JB, Fanti S, Gabriel M, Papathanasiou ND, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol. 2010;37:265–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Dörr U, Wurm K, Höring E, Guzman G, Räth U, Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Horm Metab Res Suppl. 1993;27:36–43.PubMedGoogle Scholar
  18. 18.
    Dorr U, Rath U, Sautter-Bihl M, Guzman G, Bach D, Adrian H, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med. 1993;20:431–3.CrossRefPubMedGoogle Scholar
  19. 19.
    Sabet A, Nagarajah J, Dogan AS, Biersack H-J, Sabet A, Guhlke S, et al. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Res. 2013;3:82–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    SmPC Somatuline LA [Internet]. [cited 2018 Mar 5]. Available from: https://www.medicines.org.uk/emc/product/965/smpc
  21. 21.
    Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45:836–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Brogsitter C, Zöphel K, Hartmann H, Schottelius M, Wester H-J, Kotzerke J. Twins in spirit part II: DOTATATE and high-affinity DOTATATE – the clinical experience. Eur J Nucl Med Mol Imaging. 2014;41:1158–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519–36.CrossRefPubMedGoogle Scholar
  24. 24.
    Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E. Evaluation of the interaction of amino acid infusion on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors. Clin Pharmacokinet. 2018.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineNetherlands Cancer InstituteAmsterdamThe Netherlands
  2. 2.Department of Medical OncologyNetherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Department of Endocrine OncologyUniversity Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations